Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5081-5090 Newer>

The Motley Fool September 5, 2008 Brian Orelli	Zimmer Fortifies Its Spine The medical-device maker is buying Abbott's spine business.
The Motley Fool September 5, 2008 Brian Orelli	Mindray Medical Zaps Ahead Revenue almost doubled as the company recorded two months of sales from Datascope's patient-monitoring business, which it acquired in the beginning of May.
The Motley Fool September 5, 2008 Brian Lawler	Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon.
BusinessWeek September 4, 2008 Pete Engardio	Chinese Scientists Build Big Pharma Back Home In a reverse migration, U.S.-trained scientists are setting up biotech startups, contract-research companies, and university labs on the mainland.
The Motley Fool September 4, 2008 Brian Orelli	Tapping the Brakes on the Teva-Barr Deal The FTC wants more information on this pharma merger before it offers its approval.
The Motley Fool September 4, 2008 Brian Lawler	Sitting Tight in September This month, several drugmakers will hear about compounds awaiting approval, so we can expect some volatility in their share prices. Read on to see who's awaiting FDA news.
Chemistry World September 3, 2008 Hayley Birch	Double emulsions could carry combination therapies US scientists have made nanoscale water-in-oil-in-water emulsions that could have important applications in drug delivery.
The Motley Fool September 3, 2008 Jim Mueller	Fool Poll: Vytorin, Ethics, and the Scientific Process Recent actions by pharmaceutical companies raise the question: Should preliminary data about drug effectiveness be released, or should drugmakers wait for the scientific process to be completed?
The Motley Fool September 2, 2008 Brian Orelli	Lipitor Is Back on the Tube Direct-to-consumer ads have to walk a line.
The Motley Fool September 2, 2008 Brian Orelli	Cardiologists Hate Vytorin Cardiologists seem cynical about the full presentation of Merck's and Schering-Plough's SEAS data at the European Society of Cardiology.
<Older 5081-5090 Newer> Return to current articles.